Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and hyperthermia.
Effects of a new recombinant human tumor necrosis factor (rTNF-S) on the growth of murine bladder tumor (MBT-2) were studied. The growth of MBT-2 was significantly inhibited by intratumor injection of rTNF-S. Moreover etoposide (VP-16) and hyperthermia at relatively low temperature enhanced the antitumor effect of rTNF-S. Since TNF is considered to have species preference, these observations may be relevant to treatments for human bladder tumor with human TNF.
Iizumi
T
T
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Yazaki
T
T
Waku
M
M
Soma
G
G
D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007167:Immunotherapy; D051379:Mice; D008809:Mice, Inbred C3H; D011994:Recombinant Proteins / Q000627:therapeutic use; D013045:Species Specificity; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D005047:Etoposide